216 related articles for article (PubMed ID: 23106327)
1. Case series of equine pituitary pars intermedia dysfunction in a tropical climate.
Spelta CW; Axon JE
Aust Vet J; 2012 Nov; 90(11):451-6. PubMed ID: 23106327
[TBL] [Abstract][Full Text] [Related]
2. Equine pituitary pars intermedia dysfunction.
McFarlane D
Vet Clin North Am Equine Pract; 2011 Apr; 27(1):93-113. PubMed ID: 21392656
[TBL] [Abstract][Full Text] [Related]
3. Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.
Fortin JS; Benskey MJ; Lookingland KJ; Patterson JS; Howey EB; Goudreau JL; Schott HC
BMC Vet Res; 2020 Sep; 16(1):356. PubMed ID: 32977825
[TBL] [Abstract][Full Text] [Related]
4. Equine pituitary pars intermedia dysfunction: current understanding and recommendations from the Australian and New Zealand Equine Endocrine Group.
Secombe CJ; Bailey SR; de Laat MA; Hughes KJ; Stewart AJ; Sonis JM; Tan R
Aust Vet J; 2018 Jul; 96(7):233-242. PubMed ID: 29862508
[TBL] [Abstract][Full Text] [Related]
5. Comparison of hair follicle histology between horses with pituitary pars intermedia dysfunction and excessive hair growth and normal aged horses.
Innerå M; Petersen AD; Desjardins DR; Steficek BA; Rosser EJ; Schott HC
Vet Dermatol; 2013 Feb; 24(1):212-7.e46-7. PubMed ID: 23331700
[TBL] [Abstract][Full Text] [Related]
6. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.
Menzies-Gow NJ; Banse HE; Duff A; Hart N; Ireland JL; Knowles EJ; McFarlane D; Rendle D
Equine Vet J; 2024 Mar; 56(2):220-242. PubMed ID: 37795557
[TBL] [Abstract][Full Text] [Related]
7. Investigation of single and paired measurements of adrenocorticotropic hormone for the diagnosis of pituitary pars intermedia dysfunction in horses.
Rendle DI; Duz M; Beech J; Parkin T; Durham AE
J Vet Intern Med; 2015 Jan; 29(1):355-61. PubMed ID: 25312676
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with survival, laminitis and insulin dysregulation in horses diagnosed with equine pituitary pars intermedia dysfunction.
Horn R; Bamford NJ; Afonso T; Sutherland M; Buckerfield J; Tan RHH; Secombe CJ; Stewart AJ; Bertin FR
Equine Vet J; 2019 Jul; 51(4):440-445. PubMed ID: 30417404
[TBL] [Abstract][Full Text] [Related]
9. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction.
Miller MA; Pardo ID; Jackson LP; Moore GE; Sojka JE
Vet Pathol; 2008 Jan; 45(1):26-38. PubMed ID: 18192571
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis.
Donaldson MT; Jorgensen AJ; Beech J
J Am Vet Med Assoc; 2004 Apr; 224(7):1123-7. PubMed ID: 15074858
[TBL] [Abstract][Full Text] [Related]
11. Fecal strongyle egg counts in horses with suspected pre-clinical pituitary pars intermedia dysfunction before and after treatment with pergolide.
Christen G; Gerber V; van der Kolk JH; Frey CF; Fouché N
Vet J; 2018 May; 235():60-62. PubMed ID: 29704940
[TBL] [Abstract][Full Text] [Related]
12. Pituitary pars intermedia dysfunction (Equine Cushing's disease) in an onager (Equus hemionus onager).
Peel AJ; Bouts T; Flach E; Rivers S; Routh A
J Zoo Wildl Med; 2009 Dec; 40(4):773-80. PubMed ID: 20063825
[TBL] [Abstract][Full Text] [Related]
13. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.
Beech J; Boston R; Lindborg S; Russell GE
J Am Vet Med Assoc; 2007 Aug; 231(3):417-26. PubMed ID: 17669045
[TBL] [Abstract][Full Text] [Related]
14. The use of adrenocorticotrophic hormone as a potential biomarker of pituitary pars intermedia dysfunction in horses.
Lee ZY; Zylstra R; Haritou SJ
Vet J; 2010 Jul; 185(1):58-61. PubMed ID: 20537574
[TBL] [Abstract][Full Text] [Related]
15. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
Miller AB; Loynachan AT; Bush HM; Hart KA; Barker VD; Campana-Emard AG; Grubbs ST; Adams AA
Domest Anim Endocrinol; 2021 Jan; 74():106531. PubMed ID: 32942194
[TBL] [Abstract][Full Text] [Related]
16. PITUITARY PARS INTERMEDIA DYSFUNCTION (EQUINE CUSHING'S DISEASE) IN NONDOMESTIC EQUIDS AT MARWELL WILDLIFE: A CASE SERIES. ONE CHAPMAN'S ZEBRA ( EQUUS QUAGGA CHAPMANI) AND FIVE PRZEWALSKI's HORSES ( EQUUS FERUS PRZEWALSKII).
Shotton JCR; Justice WSM; Salguero FJ; Stevens A; Bacci B
J Zoo Wildl Med; 2018 Jun; 49(2):404-411. PubMed ID: 29900762
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction.
McFarlane D; Banse H; Knych HK; Maxwell LK
J Vet Pharmacol Ther; 2017 Apr; 40(2):158-164. PubMed ID: 27301465
[TBL] [Abstract][Full Text] [Related]
18. Preliminary study on the effects of pergolide on left ventricular function in the horses with pituitary pars intermedia dysfunction.
Gehlen H; Fisch J; Merle R; Trachsel DS
J Vet Sci; 2021 Sep; 22(5):e64. PubMed ID: 34553515
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
Rendle DI; Doran G; Ireland J; Edwards S
Domest Anim Endocrinol; 2019 Jul; 68():135-141. PubMed ID: 31082785
[TBL] [Abstract][Full Text] [Related]
20. Lamellar pathology in horses with pituitary pars intermedia dysfunction.
Karikoski NP; Patterson-Kane JC; Singer ER; McFarlane D; McGowan CM
Equine Vet J; 2016 Jul; 48(4):472-8. PubMed ID: 25869529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
